Lavie, D. Et Al. 2023. waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).. JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16 .

Lavie, D., Ozcan, M., Paszkiewicz-Kozik, E., Barca, E. G., Kim, T. M., Puccini, B., ... Wang, S.(2023). waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).. JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16.

Lavie, David Et Al. "waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).," JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16, 2023

Lavie, David Et Al. "waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).." JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16, 2023

Lavie, D. Et Al. (2023) . "waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).." JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16.

@article{article, author={David Lavie Et Al. }, title={waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2023}